Literature DB >> 4871357

Plasma testosterone levels in patients with prostatic carcinoma before and after treatment.

H H Young, J R Kent.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4871357     DOI: 10.1016/s0022-5347(17)62795-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  9 in total

1.  Subcapsular orchidectomy--an effective operation?

Authors:  P D Burge
Journal:  Proc R Soc Med       Date:  1976-09

2.  Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy.

Authors:  O G van Aubel; J Bolt-de Vries; M A Blankenstein; F H de Jong; F H Schröder
Journal:  Urol Res       Date:  1989

Review 3.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

4.  Serum prolactin and tumors of the prostate: unchanged basal levels and lack of correlation to serum testosterone.

Authors:  G H Jacobi; G H Rathgen; J E Altwein
Journal:  J Endocrinol Invest       Date:  1980 Jan-Mar       Impact factor: 4.256

5.  A study of the capacity for regeneration of rat and human Leydig cells.

Authors:  T Senge; B Schenck; U Tunn; T Hülshoff; F Neumann
Journal:  Urol Res       Date:  1978

6.  Gestagens in the management of prostatic carcinoma.

Authors:  Z Szendröi
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

7.  Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.

Authors:  M R Robinson; B S Thomas
Journal:  Br Med J       Date:  1971-11-13

8.  Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

Authors:  S O Andersson; H O Adami; R Bergström; L Wide
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Leuprorelin depot injection: patient considerations in the management of prostatic cancer.

Authors:  Zinelabidine Abouelfadel; E David Crawford
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.